The way soreness began tells you how soon to seek care

Fever, chest symptoms, or a changed shoulder shape need urgent care

Seek urgent help when an injury leaves the shoulder misshapen. Fever with a joint that is hot, red, and swollen can mean infection. Prompt care is also needed for severe soreness, redness that spreads, or fluid coming from a recent procedure site.

Shoulder discomfort needs emergency care when it comes with sweating, shortness of breath, nausea, or chest tightness, because the cause may not be the shoulder and waiting for a clinic appointment could be unsafe. New hand weakness or numbness may come from the neck and needs an exam. Tell the examiner about cancer, weight loss, or night sweats.

A clinic consultation isn't the right place for these warning signs.

A routine visit should connect the exam to your daily limits

Write down how the ache started and whether an injury caused it. Note which reach hurts, whether the arm feels weak, and what wakes you. Carry a written record of your medicines plus any past scan. The examiner uses these facts to check the tendon, joint surface, and neck.

Ask which movements are safe at home and when another visit is due. If someone offers a paid procedure, ask how much relief is likely. Also ask which choice follows when soreness remains. The answer should fit your exam and daily limits.

At QC Kinetix in Chandler, medical providers are clinic staff who examine shoulders and discuss regenerative treatments that don't require surgery.

Sources

1. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

3. In the MOON Shoulder prospective cohort of 452 patients with symptomatic, ATRAUMATIC full-thickness rotator cuff tears, physical therapy succeeded in more than 70% of patients at 10 years: only 115 (27.0%) had surgery at any point over the decade. Patient-reported outcomes improved with physical therapy and did NOT decline over 10 years in those who never had surgery. The strongest predictor of early surgery was low patient expectation of physical therapy, not tear anatomy.

   Kuhn JE, et al. — The Predictors of Surgery for Symptomatic, Atraumatic Full-Thickness Rotator Cuff Tears Change Over Time: Ten-Year Outcomes of the MOON Shoulder Prospective Cohort.. J Bone Joint Surg Am, 2024. DOI: 10.2106/JBJS.23.00978.

4. FDA states verbatim that stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products 'have [not] been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

5. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development study. There is no Medicare national coverage for PRP in shoulder osteoarthritis or rotator cuff disease, which is why these injections are billed to the patient directly.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.